Dupilumab-induced psoriasis in a patient with atopic dermatitis successfully treated with Upadacitinib: A case report
Dupilumab, a monoclonal antibody that targets interleukin-4 and interleukin-13, is one of the approved biologic treatments for moderate-to-severe atopic dermatitis. While it is extremely well tolerated with low rates of adverse events, there have been reports of patients with atopic dermatitis manag...
Saved in:
Main Authors: | Katrina D Cirone, Fiona E Lovegrove |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2025-02-01
|
Series: | SAGE Open Medical Case Reports |
Online Access: | https://doi.org/10.1177/2050313X251317811 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Successful Use of Dupilumab in the Treatment of Acquired Perforating Dermatosis Associated with Atopic Dermatitis
by: Niccolò Gori, et al.
Published: (2024-01-01) -
Case Report: Severe ophiasis-pattern alopecia areata with concomitant atopic dermatitis in a 5-year-old boy successfully treated with dupilumab
by: Zhendong Wei, et al.
Published: (2025-02-01) -
Successful Achievement of Demanding Outcomes in Upadacitinib-Treated Atopic Dermatitis Patients: A Real-World, 96-Week Single-Centre Study
by: Stamatios Gregoriou, et al.
Published: (2025-01-01) -
Rosacea-like skin reaction under treatment with dupilumab for atopic dermatitis
by: C. Grote, et al.
Published: (2025-12-01) -
Subcutaneous immunotherapy in a patient taking ofatumumab for multiple sclerosis and upadacitinib for atopic dermatitis
by: Twan Sia, BA, et al.
Published: (2025-05-01)